Qiagen N.V. (NYSE:QGEN) Stock Has Consensus Price Target of $43.51

Shares of Qiagen N.V. (NYSE:QGEN) have earned an average rating of “Hold” from the fourteen ratings firms that are presently covering the firm, MarketBeat.com reports. Nine research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $43.51.

A number of brokerages have issued reports on QGEN. Weiss Ratings raised shares of Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 11th. Citigroup reissued a “neutral” rating and issued a $45.00 target price (up from $38.00) on shares of Qiagen in a report on Monday, August 10th. Jefferies Financial Group restated a “buy” rating and set a $48.00 target price on shares of Qiagen in a research report on Thursday, August 6th. JPMorgan Chase & Co. raised their target price on shares of Qiagen from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Kepler Capital Markets set a $38.60 price target on shares of Qiagen and gave the company a “hold” rating in a report on Thursday, June 25th.

Qiagen Stock Performance

NYSE QGEN opened at $45.07 on Friday. The firm has a market cap of $9.29 billion, a price-to-earnings ratio of 23.10, a price-to-earnings-growth ratio of 4.40 and a beta of 0.63. The company has a quick ratio of 2.31, a current ratio of 2.85 and a debt-to-equity ratio of 0.48. The business has a 50-day moving average price of $42.88 and a 200-day moving average price of $39.88. Qiagen has a twelve month low of $32.53 and a twelve month high of $57.81.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The firm had revenue of $535.04 million during the quarter, compared to analysts’ expectations of $527.50 million. During the same quarter last year, the business posted $0.60 earnings per share. The firm’s revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, equities research analysts predict that Qiagen will post 2.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Qiagen

Several large investors have recently made changes to their positions in the company. Deutsche Bank AG raised its holdings in shares of Qiagen by 9.7% during the 4th quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after acquiring an additional 697,342 shares in the last quarter. Amundi boosted its position in shares of Qiagen by 12.4% during the 1st quarter. Amundi now owns 4,757,681 shares of the company’s stock valued at $190,498,000 after acquiring an additional 524,959 shares during the last quarter. Norges Bank purchased a new position in shares of Qiagen in the fourth quarter valued at $166,500,000. Capital International Investors grew its holdings in shares of Qiagen by 11.4% in the fourth quarter. Capital International Investors now owns 2,587,505 shares of the company’s stock valued at $116,361,000 after purchasing an additional 264,412 shares in the last quarter. Finally, State Street Corp increased its position in Qiagen by 4.5% in the second quarter. State Street Corp now owns 2,183,206 shares of the company’s stock worth $85,363,000 after purchasing an additional 93,575 shares during the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Company Profile

QIAGEN N.V. is a global provider of sample preparation, molecular testing and bioinformatics solutions used in life sciences research, molecular diagnostics and applied testing. The company develops technologies that help customers isolate and analyze DNA, RNA and other biological materials from blood, tissue and other samples.

Its offerings include laboratory instruments, consumables, assay kits and software. Key product areas include automated sample-processing systems, polymerase chain reaction (PCR) and digital PCR solutions, next-generation sequencing workflows, bioinformatics tools, and diagnostic tests such as QuantiFERON for tuberculosis testing and QIAstat-Dx for syndromic testing.